Quality of life was assessed in 57 patients with limited small-cell carcinoma of the lung utilizing psychological scales that measured mood, functional status, and cognitive impairment. These patients received chemotherapy with or without radiotherapy to the primary tumor. All patients received prophylactic cranial radiation. Patients who received the combination of chemotherapy and radiotherapy to both the primary tumor and CNS had an increase in overall survival. However, because of the increased toxicity experienced by these patients, a decrease in quality of life was documented by measures of psychological distress when compared to patients receiving chemotherapy alone. The findings support the importance of utilizing quality of life measures in addition to measures of physical toxicity so that patients can make an informed choice regarding treatment options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000288922 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses.
Curr Med Chem
January 2025
Shree S K Patel College of Pharmaceutical Education and Research, Ganpat University, Mahesana, Gujarat, 384012, India.
Therapeutic hurdles persist in the fight against lung cancer, although it is a leading cause of cancer-related deaths worldwide. Results are still not up to par, even with the best efforts of conventional medicine, thus new avenues of investigation are required. Examining how immunotherapy, precision medicine, and AI are being used to manage lung cancer, this review shows how these tools can change the game for patients and increase their chances of survival.
View Article and Find Full Text PDFDevelopment of an Innovative Decision-Aid to Better Align Patients' Implantable Cardioverter Defibrillator Shock Status With Goals of Care.
Circ Cardiovasc Qual Outcomes
January 2025
Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (S.G., Nimesh Patel, M.K., M.S.S.).
Concurrent management of vitiligo and acquired disorders of hyperpigmentation: a comprehensive literature review and current practice gaps.
Int J Dermatol
January 2025
Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Few studies discuss the co-management of vitiligo and acquired hyperpigmentation disorders (AHD) such as melasma, erythema dyschromicum perstans, post-inflammatory hyperpigmentation, drug-induced hyperpigmentation, and lichen planus pigmentosus. This review discusses clinical studies examining co-management strategies and identifies current practice gaps. Dermatology Life Quality Index scores are higher in individuals with vitiligo or melasma.
View Article and Find Full Text PDFExploring the association between pro-inflammatory mediators and sarcopenia in cancer patients through different diagnostic tools: a narrative review.
Ann Transl Med
December 2024
Post-Graduation Department, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil.
Background And Objective: Sarcopenia, characterized by the progressive loss of skeletal muscle mass (MM) and muscle function, is a common and debilitating condition in cancer patients, significantly impacting their quality of life, treatment outcomes, and overall survival. The pathophysiology of sarcopenia is multifactorial, involving metabolic, hormonal, and inflammatory changes. Recent research highlights the role of chronic inflammation in the development and progression of sarcopenia, with pro-inflammatory cytokines being key mediators of muscle catabolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!